Ferrous Sulfate 325 MG tablet; NDC 33261-0715-00
Aidarex Pharmaceuticals
Presence of Foreign Tablets/Capsules
95,075 total recalls in our database
Aidarex Pharmaceuticals
Presence of Foreign Tablets/Capsules
Mylan Pharmaceuticals
cGMP Deviations; cleaning processes for equipment used to manufacture the specified batches was not followed according to procedure
Milbar Laboratories
GMP Deviations
Mylan Pharmaceuticals
cGMP Deviations; cleaning process for equipment used to manufacture the specified batches was not followed according to procedure
Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).
Sun Pharmaceutical Industries
Labeling: Not Elsewhere Classified: Sun Pharma has decided to initiate this recall in response to identified labeling discrepancies in the patient literature.
Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).
Milbar Laboratories
Microbial Contamination of Non-sterile Product
Presence of Particulate Matter: confirmed customer report for presence of visible particulate matter, confirmed as glass
Defective delivery system
Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).
Labeling: Labeling Error on Declared Strength; The outer carton (secondary packaging) statement of ingredients misstates the concentration of active ingredient at 7%. The primary packaging (tube) correctly states the active ingredient at 10%.
Milbar Laboratories
GMP Deviations
Sun Pharmaceutical Industries
Presence of Foreign Substance:Sun Pharma is recalling one (1) lot of Sulfamethoxazole and Trimethoprim Tablets USP, 800 mg/160 mg (500 ct.) because a foreign matter identified as polyethylene was detected in two (2) tablets.
Device may be missing a sled component. The sled component is responsible for staple deployment. This may result in failure to form a staple line when tissue is divided, leading to bleeding or leakage of luminal contents.
Epic Extremity
There is an error in the caddy artwork that misidentifies a specific plate and screw.
Device may be missing a sled component. The sled component is responsible for staple deployment. This may result in failure to form a staple line when tissue is divided, leading to bleeding or leakage of luminal contents.
Software anomaly resulting in the loss of patient settings and stored patient data.
Kelyniam Global
Significant design changes made to the Custom Skull Implant (CSI) devices, such as removing pressure relief holes across the length of the device and adding suture holes along the ridge of the implant, were not validated or submitted to FDA for marketing clearance. The Temporal Suture System (TSS) is no longer being offered and the Integrated Fixation System (IFS) has been temporarily suspended
Device may be missing a sled component. The sled component is responsible for staple deployment. This may result in failure to form a staple line when tissue is divided, leading to bleeding or leakage of luminal contents.